-
National Health And Wellness Commission: No contribution can not be named papers! Not tied to performance or bonuses
Time of Update: 2021-03-24
Within 1 month after the publication of relevant papers and other scientific research results , To submit the original information to the institution After the completion of the research, medical scientific research personnel shall follow the corresponding biosafety and scientific research management regulations for the storage, sharing and destruction of human or animal samples, toxic substances, data or materials.
-
Yang Jiafang reveals to you the various causes of repeated vitiligo
Time of Update: 2021-03-24
Failure to follow the doctor's instructions, some patients with vitiligo, usually busy with work and other external factors, forget to treat or stop the treatment when they get a little better, resulting in the skin color has not returned to normal, and the damaged melanocytes have not been completely repaired.
-
AstraZeneca Class 1 new drug approved in China for clinical development to treat breast cancer
Time of Update: 2021-03-24
It is expected that the clinical study of AstraZeneca is oral estrogen receptor degradation agent AZD9833 in China will proceed smoothly, bringing new treatment options to breast cancer patients.
-
FDA issues third emergency use authorization for new crown vaccine
Time of Update: 2021-03-24
Today, the US FDA issued the third emergency use authorization (EUA) for the new coronavirus vaccine to prevent the new coronavirus pneumonia (COVID-19) caused by severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) 18 Individuals aged and over.
-
National revised norms for medical researchers and institutions: Do not step on the "red line"!
Time of Update: 2021-03-24
The third is to strengthen results management and establish a traceability mechanism for the entire process of scientific research results.
The third is to strengthen results management and establish a traceability mechanism for the entire process of scientific research results.
-
Last week 25 generic drugs passed the consistency evaluation and seven became injections
Time of Update: 2021-03-24
The Insight database shows that there are currently 7 companies submitting supplementary applications for consistency evaluation of Palonosetron Hydrochloride Injection, 4 companies have submitted applications for listing on the new registration classification, and 1 company is in the BE trial stage.
-
Health care committee replied to the NPC recommendations: high-value medical supplies adjusted out of the disposable equipment catalog
Time of Update: 2021-03-24
Reply to the suggestions made One-time use of high-value medical consumables may cause waste of resources, environmental pollution and rising medical costs.
Reply to the suggestions made One-time use of high-value medical consumables may cause waste of resources, environmental pollution and rising medical costs.
-
The net profit of 9 Chinese medicine companies exceeded 100%!
Time of Update: 2021-03-23
Zuoli Pharmaceuticals stated in the performance forecast that taking advantage of the core products Wuling Capsules, Bailing Tablets, and Lingze Tablets to enter the National Essential Drug List, increasing market investment and the development and coverage of terminal medical institutions are the main factors for performance growth.
-
Who will be the first Axl selective inhibitor to be marketed?
Time of Update: 2021-03-23
In view of the multiple roles of AXL in tumor cells, the development of AXL inhibitors is considered to have two main directions, one is the treatment of drug-resistant tumors, and the other is Combined with the same "pass killing" immunotherapy, it can enhance the lethality against heterogeneous tumors.
-
Challenge Kelun's leading position!
Time of Update: 2021-03-23
According to data from Meinenet, the sales of terminal bromhexine hydrochloride injections in China's public medical institutions exceeded 2 billion yuan in 2019.
According to data from Meinenet, the sales of terminal bromhexine hydrochloride injections in China's public medical institutions exceeded 2 billion yuan in 2019.
-
National Medical Insurance Bureau: 49 cities across the country have piloted long-term care insurance
Time of Update: 2021-03-23
Wang Zhenhua, Section Chief of the Non-Basic Medical Insurance Section of the Medical Insurance Bureau of Wenjiang District, Chengdu: It has a prerequisite for long-term severe disability of more than 6 months due to illness, disability and other reasons, and there is no age limit.
-
"Angel" or "devil"?
Time of Update: 2021-03-23
Similar to "fentanyls", oxycodone has long been included in the narcotic control list, but its good effects can still occupy a place in the market.
In the analgesic family, such as dezocine, fentanyl and sufentanil, oxycodone all have good market prospects, although they are included in various control lists.
-
Buchang Pharmaceutical Xuanfeibaidu Granules Approved for Listing
Time of Update: 2021-03-23
On March 4, Buchang Pharmaceutical issued an announcement stating that it had recently received the "Drug Registration Certificate" on Xuanfeibaidu Granules approved and issued by the State Food and Drug Administration.
-
Successfully promote hair regrowth! Eli Lilly's JAK inhibitor reaches phase 3 clinical endpoint
Time of Update: 2021-03-23
Today, Eli Lilly and Company and Incyte jointly announced that the oral JAK inhibitor baricitinib has reached the primary endpoint in a phase 3 clinical trial for the treatment of adult patients with severe alopecia areata (alopecia areata).
-
Xu Xiaofeng, general manager of Roche's general medicine division and specialty medicine division in China, resigns
Time of Update: 2021-03-23
After his departure from Roche Pharmaceuticals, the Specialty Drugs Division was temporarily managed by Qian Wei, Vice President of Roche Oncology First Division.
Later, he served as Vice President of General Medicines Division and Specialty Medicines Division and participated in the formulation of many core strategies of Roche Pharmaceuticals China.
-
GSK Central Nervous Drugs Approved in China for New Indications for Treatment of Bipolar Disorder
Time of Update: 2021-03-23
On March 3, GlaxoSmithKline (GSK) issued a press release stating that the new indications of Rapidone (generic name: Lamotrigine Dispersible Tablets) have been approved by the National Medical Products Administration (NMPA).
-
Health Commission: A large number of hospitals are restricted in surgery (list attached)
Time of Update: 2021-03-23
cn/news/yyzb/" target="_blank">purchase of consumables may drop After the list of restricted medical technologies is released, for the medical device industry, restricting the development of medical technologies means that related operations will be reduced, and the use of some equipment and consumables involved in operations will also be sharply reduced.
-
The review of AstraZeneca's anemia drug roxadustat was postponed again by the FDA
Time of Update: 2021-03-23
CompilationFan DongdongOn Monday, AstraZeneca and FibroGen said that the FDA will convene an AdComm advisory committee to review the effectiveness of roxadustat in the treatment of anemia in patients with chronic kidney disease who require dialysis and those who do not require dialysis.
-
determine!
Time of Update: 2021-03-23
cn/news/yyzb/" target="_blank">Purchasing Department of the National Medical Insurance Bureau previously stated that compared with the third batch of national drug collections, the fourth batch of drug collections further fine-tuned and optimized the procurement rules, increasing the number of companies that can be selected from the original 8 to 10 companies to further improve their supply guarantee capabilities.
-
From March 1st, the "crime of dereliction of duty in drug supervision" came
Time of Update: 2021-03-23
Medical Network News, March 2 On February 27, the official website of the Supreme People's Procuratorate issued the "Supplementary Provisions on the Implementation of the Criminal Law of the People's Republic of China on Determining Crimes (7)" (hereinafter referred to as the "Supplementary Provisions").
